Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in Myelofibrosis
NCT00095784Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in myelofibrosis (MF), sponsored by National Cancer Institute. Primary endpoints: Response Rate (Complete Response, Partial Response, or Hematologic Improvement) at 36 weeks and Incidence of Toxicities, Graded According to NCI CTCAE v3.0. Started Sep 2004; status: active, not recruiting.
02
Drugs
decitabine
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00095784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095784.